Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

LEUVEN, Belgium, May 13 /PRNewswire-FirstCall/ --

- Regulated Information

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for vascular disease, eye disease and cancer, is today issuing a business update for the three month period ended 31 March 2008.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs are continuing to make the good progress that we had anticipated. During the first three months of 2008, we achieved a number of important clinical milestones that have clearly added further value to our exciting product pipeline. The positive results of our trials with microplasmin are giving us confidence that it has the potential to make a real difference in the field of eye disease. Our exciting new anti-cancer antibody TB-403 has also begun its clinical development. We anticipate seeing further encouraging results across our development pipeline during the remainder of 2008; a year in which we expect to advance ThromboGenics' business significantly."

Financial Update

- In the first quarter of 2008, revenue amounted to EUR 0.1 million, mainly coming from out-licensing. Operating expenses were EUR 3.2 million in the first quarter, the majority of which were due to R&D expenses related to our increasing number of clinical development programs.

- As of 31 March 2008, ThromboGenics had EUR 41.7 million in cash and cash equivalents. This compares to EUR 29.1 million on 31 March, 2007 and EUR 46.1 million on 31 December 2007.

Clinical Update

Highlights

- ThromboGenics completed patient enrolment for its Phase IIb MIVI III trial in the United States for microplasmin in vitrectomy.

Microplasmin is being developed as an adjunct for vitrectomy. A vitrectomy is an increasingly common surgical procedure which is carried out in the treatment of many back of the
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Research and Markets  has announced the ... & Services, End-User , Application - Global Forecast to ... The global oligonucleotide synthesis market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... the basis of products and services, applications, end users, ...
(Date:9/29/2014)... diseases and biodiversity loss requires evolutionary thinking, argues ... Express that was co-authored by Bruce Tabashnik ... and Life Sciences. , For the first time, ... progress in addressing a broad set of challenges ... that consider evolutionary histories and the likelihood of ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Iceland, Jan. 4 deCODE genetics,(Nasdaq: DCGN ) ... of deCODE,CEO Kari Stefansson,s presentation at the JPMorgan 26th ... 11:30 am PST / 7:30 pm GMT on,Thursday, January ... webcast can be accessed through the Investors page on ...
... to study technology to reduce greenhouse gas emissions, ... Midland,Company (NYSE: ADM ), the Midwest Geological ... (ISGS) announce that they are,working together on a ... and storage of carbon dioxide from ADM,s ethanol ...
... development programs, including review of positive results from the Phase ... ... Jan. 4 QuatRx Pharmaceuticals Company,today announced that the company chief ... 26th Annual JP Morgan Healthcare,Conference on Tuesday, January 8th, 2008, at ...
Cached Biology Technology:ADM, MGSC and ISGS Announce Carbon Sequestration Project 2ADM, MGSC and ISGS Announce Carbon Sequestration Project 3QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2
(Date:9/29/2014)... Genome Institute (DOE JGI), a DOE Office of ... projects have been selected for the 2015 Community ... Caribbean waters, and from plant root micro-ecosystems, to ... watersheds, the CSP 2015 projects portfolio highlights diverse ... , "These projects catalyze JGI,s strategic shift ...
(Date:9/29/2014)... The BRAF inhibitor dabrafenib has significant anti-tumour activity ... cell lung cancer whose disease has progressed after ... the ESMO 2014 Congress in Madrid, Spain. ... BRAF have generated considerable interest because these mutations ... tyrosine-kinase inhibiting agents," says lead author Dr David ...
(Date:9/29/2014)... Oktoberfest is here, and that means ... for a cold one, taking that first ... chemicals have reacted to form compounds that ... Reactions explains why beers get skunky, and ... brews from going bad. Learn all about ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3
... along the Mississippi River and other areas are altering ... a researcher from Iowa State University. Fred Janzen, ... studied turtle nesting habits and also accumulated research going ... the turtles to find out when they make nests ...
... snakes may slither in saltwater, but they sip the ... zoologist in a paper appearing this month in the ... Physiological and Biochemical Zoology . Harvey Lillywhite ... roughly 60 species of venomous sea snakes worldwide satisfy ...
... incoming administration will confront an array of threats and ... American president, says Steve Fetter, dean of the University ... won, Fetter asked six experts on his faculty with ... recommending steps to address key challenges. Most ...
Cached Biology News:Turtles alter nesting dates due to temperature change says ISU researcher 2Zoologists: Sea snakes seek out freshwater to slake thirst 2Zoologists: Sea snakes seek out freshwater to slake thirst 3Advice to the new administration: UM foreign and domestic policy guide 2Advice to the new administration: UM foreign and domestic policy guide 3Advice to the new administration: UM foreign and domestic policy guide 4Advice to the new administration: UM foreign and domestic policy guide 5Advice to the new administration: UM foreign and domestic policy guide 6Advice to the new administration: UM foreign and domestic policy guide 7
...
Contains L-glutamine....
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
...
Biology Products: